Cargando…

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan

IMPORTANCE: Financial relationships between pharmaceutical companies and physicians can bias the conduct, findings, and reporting of clinical trials. In Japan, the valsartan scandal was a significant event: all 5 key articles on the valsartan clinical trials were retracted after the revelation of da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawano, Toyoaki, Ozaki, Akihiko, Saito, Hiroaki, Shimada, Yuki, Tanimoto, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537813/ https://www.ncbi.nlm.nih.gov/pubmed/31099864 http://dx.doi.org/10.1001/jamanetworkopen.2019.3817

Ejemplares similares

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan
por: Saito, Hiroaki, et al.
Publicado: (2019)

Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
por: Murayama, Anju, et al.
Publicado: (2020)

Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016
por: Shimada, Yuki, et al.
Publicado: (2019)

Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension
por: Senoo, Yuki, et al.
Publicado: (2021)

Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis
por: Ozaki, Akihiko, et al.
Publicado: (2019)

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Kusumi, Eiji, et al.
Publicado: (2022)

Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies
por: Murayama, Anju, et al.
Publicado: (2021)

How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
por: Ozaki, Akihiko, et al.
Publicado: (2022)

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Will initial consultation patterns among undiagnosed cancer patients be the same after this COVID-19 pandemic? Experiences from the 2011 triple disaster in Fukushima, Japan
por: Ozaki, Akihiko, et al.
Publicado: (2020)

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
por: Kobashi, Yurie, et al.
Publicado: (2019)

Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians
por: Murayama, Anju, et al.
Publicado: (2022)

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Nosocomial SARS-CoV-2 Infections in Japan: A Cross-sectional Newspaper Database Survey
por: Tani, Yuta, et al.
Publicado: (2020)

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
por: Ozieranski, Piotr, et al.
Publicado: (2023)

Underperformance of Reverse-Transcriptase Polymerase Chain Reaction in Japan and Potential Implications From Diamond Princess Cruise Ship and Other Countries During the Ongoing COVID-19 Pandemic
por: Yamamoto, Kana, et al.
Publicado: (2020)

Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020
por: Murayama, Anju, et al.
Publicado: (2022)

Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels
por: Nusrat, Salman, et al.
Publicado: (2018)

Trends in Industry Payments to Diabetologists and Endocrinologists in the United States During the COVID-19 Pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

Research and Nonresearch Industry Payments for COVID-19 mRNA Vaccines in the United States
por: Murayama, Anju, et al.
Publicado: (2023)

Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

The Trend in Industry Payments During the COVID-19 Pandemic Among Gastroenterologists and Hepatologists in the United States
por: Murayama, Anju, et al.
Publicado: (2022)

The Pharmaceutical Profession and the 'Drugs Scandal'
Publicado: (1934)

Japan’s Drug Regulation Framework: Aiming for Better Health or Bigger Profits?
por: Ozaki, Akihiko, et al.
Publicado: (2020)

Error in Payments From Some Pharmaceutical Companies
Publicado: (2019)

Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019
por: Kamamoto, Sae, et al.
Publicado: (2023)

Social isolation and cancer management – advanced rectal cancer with patient delay following the 2011 triple disaster in Fukushima, Japan: a case report
por: Ozaki, Akihiko, et al.
Publicado: (2017)

The long term participation trend for the colorectal cancer screening after the 2011 triple disaster in Minamisoma City, Fukushima, Japan
por: Saito, Hiroaki, et al.
Publicado: (2021)

Interruption of breast cancer care and importance of inter‐hospital cooperation during the COVID‐19 pandemic: A case report of advanced breast cancer in Fukushima, Japan
por: Ozaki, Akihiko, et al.
Publicado: (2022)

Are the issues pointed out by ChatGPT can be applied to Japan? - Examining the reasons behind high COVID-19 excess deaths in Japan
por: Kaneda, Yudai, et al.
Publicado: (2023)

Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
por: Mitchell, Aaron P, et al.
Publicado: (2022)

The Scandal of "Hospital Scandals"
Publicado: (1900)

Negative Aspects of the Regional Quota System in Japan
por: Yamamoto, Kana, et al.
Publicado: (2019)

Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
por: Mamada, Hanano, et al.
Publicado: (2023)

Association between COVID-19 incidence and postponement or cancellation of elective surgeries in Japan until September 2020: a cross-sectional, web-based survey
por: Kurokawa, Tomohiro, et al.
Publicado: (2022)

Exacerbation of Subthreshold PTSD Symptoms in a Great East Japan Earthquake Survivor in the Context of the COVID-19 Pandemic
por: Hori, Arinobu, et al.
Publicado: (2021)

Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_php0fnts1qjc724a3ucac3b2c2